RxDoctor Payments Data

Kevin McMahon, MD

Neurology · Seguin, TXNPI 1124339528

Payments from drug & device makers

$1,228in general payments, 2019–2025

Across 53 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$277
  • AbbVie$170
  • UCB, Inc.$141
  • Ceribell, Inc.$128
  • Pfizer$106
  • Acadia Pharmaceuticals Inc$89
  • plus $317 from 10 others

What the payments were for

  • Food & beverage$1,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,228 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$29,707
Medicare patients
144
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate29$143,347
EpidiolexCannabidiol (Cbd)17$80,803
Nurtec OdtRimegepant Sulfate26$49,666
GocovriAmantadine Hcl14$47,209
XcopriCenobamate28$44,846
Rasagiline Mesylate120$14,499
Lacosamide55$7,677
Levetiracetam118$5,029
Carbidopa-LevodopaCarbidopa/Levodopa235$3,117
Piroxicam13$2,946
Lamotrigine ErLamotrigine22$2,857
Carbidopa-Levodopa ErCarbidopa/Levodopa44$2,764
Lamotrigine OdtLamotrigine13$2,590
Memantine Hcl ErMemantine Hcl23$2,101
Ropinirole ErRopinirole Hcl22$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$89$143,34729 claims
PfizerNurtec Odt$106$49,66626 claims
SK Life Science, Inc.Xcopri$277$44,84628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →